Sutro Biopharma Analyst Ratings
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating, Cuts Target Price to $15
Truist Financial Sticks to Their Buy Rating for Sutro Biopharma (STRO)
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $8 to $17
Sutro Biopharma's Strong Financials and Clinical Progress Reinforce Buy Rating
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $5 to $12
Wedbush Sticks to Its Buy Rating for Sutro Biopharma (STRO)
Sutro Biopharma Analyst Ratings
Sutro Biopharma: A Stable Hold Amidst Anticipated Trial Updates and Market Perceptions
Buy Rating Affirmed for Sutro Biopharma on Promising Luvelta and Bevacizumab Combination Therapy
TD Cowen Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Bank of America Securities Sticks to Its Buy Rating for Sutro Biopharma (STRO)
Sutro Biopharma (STRO) Gets a Hold From Wells Fargo
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)
Sutro Biopharma Analyst Ratings
Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
Oppenheimer Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Sutro Biopharma Analyst Ratings
Buy Rating on Sutro Biopharma: Promising Trials and Market Expansion Potential for Luvelta
Sutro Biopharma Analyst Ratings